Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.

NEW YORK, Sept. 11 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH). The full 60-page report can be found at

Tapestry Pharmaceuticals, Inc. ("Tapestry" or "the Company") is a biopharmaceutical company developing New Chemical Entities that may be effective in treating a broad spectrum of cancers. The Company's lead compound, TPI 287, is a novel, proprietary, third-generation taxane. Although taxanes have been used as cancer therapies for many years, treatment with these drugs is often plagued by undesirable effects, the most notable of which is the emergence of multi-drug resistance (MDR). To address this, Tapestry is developing TPI 287, which has shown the ability to overcome MDR in preclinical experiments.

In particular, TPI 287 targets MDR-1 (the primary mechanism responsible for tumor resistance to taxanes). TPI 287 has also shown efficacy in preclinical studies in a broad range of cell lines versus comparator drugs. Furthermore, in animal models, TPI 287 has shown greater oral bioavailability than paclitaxel, an approved taxane.

The Company filed an Investigational New Drug (IND) application for TPI 287 with the U.S. Food and Drug Administration (FDA) and commenced two Phase 1 studies, each with a different dosing regimen. The first Phase 1 study, which began in January 2005, employed a Q7D X3 regimen (dosing every seven days for three weeks), while the second Phase 1 study, which started in January 2006, used a Q21D (dosing every 21 days) regimen. The objectives of these Phase 1 trials were to determine the maximum tolerated dose (MTD) to be used in Phase 2 studies as well as to determine the safety, anti-tumor, and pharmacokinetic and pharmacodynamic profiles of TPI 287. In October 2006, the Company reached the MTD of its second Phase 1 trial. The Company is headquartered in Boulder, Colorado, with offices in New Jersey and New York.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of forty seven thousand five hundred dollars for its services in creating this report, for updates, and for printing costs

Forward-Looking Safe Harbor Statement

Statements in this news release regarding the potential effectiveness of TPI 287 in treating a broad spectrum of cancers and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from the results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties, and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of protocols, negotiations with regulatory agencies, or other factors, and that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that the Company is blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that the Company is limited in its ability to obtain, maintain, and enforce its own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional information on factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-K, 10-Q, and any other forms filed by the Company with the Securities and Exchange Commission.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.

SOURCE Crystal Research Associates, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Government To Clamp Down On Crystal Meth
2. Insulin Crystals Holds Promise In Diabetes research
3. Does Aspirin Crystallize?
4. Cellulose Nanocrystal Research Paves the Way for Newer Vaccines, Computer Inks
5. Human Membranes Crystal Structure may Help Tailor Asthma Drugs
6. Kidney Stones - Interesting New Research implicates bacteria as its cause
7. Stem cell research- now Nobel Laureates join the debate
8. Researchers urge caution in using ear tube surgery
9. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
10. Spouses and other partners lower blood pressure says new research
11. Researchers Scale to assess the Severity of Epilepsy in Kids
Post Your Comments:
(Date:11/25/2015)... ... 25, 2015 , ... Students and parents have something to be thankful for ... Real Impact awards. California Casualty is proud to support the contest designed ... and reckless driving, the number one killer of young drivers. , Almost 1,000 ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... ... now certified to offer their patients the many benefits of the revolutionary BIOLASE ... the sharp cutting and scraping tools traditionally used by a dentist in ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide ... Angela Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, ... fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient ...
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... national leaders when it comes to several aspects of orthopedic care. They have ... replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review selected ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ... NASDAQ: EPIX ) announced today that the first ... study of EPI-506 as a treatment for metastatic castration-resistant ... and Canada.  --> ... --> In the Phase 1/2 clinical trial, ESSA ...
(Date:11/24/2015)... --> --> According to ... Type (Bone Graft, Bine Graft Substitute, Platelet Rich Plasma, BMAC), ... Fusion), End User, and Geography - Global Forecast to 2020", ... Billion in 2014 and is expected to reach $2.4 Billion ... period of 2015 to 2020. Browse 55 market ...
Breaking Medicine Technology: